Skip to main content

Market Overview

Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS), according to Leerink.

The Gilead Sciences Analyst

Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94.

The Gilead Sciences Thesis

Remdesivir is likely to be sold for both commercial use and government stockpiles, reaching a revenue peak of $7.7 billion in 2022, Porges said in the Wednesday upgrade note.

Stockpile sales could begin by late 2021, the analyst said, adding that he expects the commercial price of remdesivir to be $5,000 per course in the U.S., $4,000 in Europe and $2,000 in other markets.

Although there is a great deal of uncertainty around the revenue and profit contribution from remdesivir, Gilead Sciences has other opportunities from the successful development of its expanded pipeline, Porges said. 

The recently announced deal with Arcus Biosciences provides Gilead with “critical mass in oncology with a diverse and synergistic pipeline, and boosts our confidence for investing in the stock long term,” the analyst said. 

Leerink raised its earnings estimates for 2020 and 2021 from $6.66 per share to $6.80 per share and from $7.01 per share to $7.74 per share, respectively.

GILD Price Action

Shares of Gilead Sciences were up 1.04% at $74.02 at the time of publication Wednesday. 

Related Links: 

Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19

The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer

Latest Ratings for GILD

Apr 2021SVB LeerinkMaintainsOutperform
Apr 2021Morgan StanleyMaintainsOverweight
Apr 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for GILD
View the Latest Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19Analyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

TSPOppenheimerInitiates Coverage On55.0
RXRXJP MorganInitiates Coverage On32.0
HALOPiper SandlerDowngrades48.0
SDCJP MorganDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at